Clinical trial · Observational
The Myeloid Neoplasms Biology and Outcome Project
A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Myeloid Neoplasms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Myeloid Neoplasms Biology and Outcome Project (MyBOP) aims to establish a registry study for patients with myeloid neoplasms. It integrates clinical data, biological samples, socio-demographic information, long-term follow-up and patient reported outcomes in a structured manner for scientific purposes. The ultimate benefits are: 1. Improvement of evidence-based clinical management of patients with myeloid neoplasms through better understanding of the course of disease and prognostic and predictive parameters 2. Direct access to new and personalized treatment approaches through recruitment into clinical studies based on the myeloid neoplasms study platform 3. Quality assurance of participating centers by evaluating and comparing clinical outcomes and side effects of the MyBOP patients with published data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloid Neoplasm | Myeloid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- median overall survival (mOS)
- timeFrame
- 5 years
- description
- Time period of survival from date of diagnosis of myeloid neoplasy
- measure
- overall survival (mOS)
- timeFrame
- 10 years
- description
- Time period of survival from date of diagnosis of myeloid neoplasy
- measure
- event free survival (EFS)
- timeFrame
- 5 years
- description
- Time period of event free survival from date of diagnosis of myeloid neoplasy
- measure
- progression free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected or proven diagnosis of Myeloid Neoplasms according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues * Age ≥18 years * Ability to understand the nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
References
Publications (0)
Data not yet available